financetom
Business
financetom
/
Business
/
Halmont Properties 2024 Profit Decreases
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Halmont Properties 2024 Profit Decreases
May 25, 2025 8:43 PM

07:48 AM EDT, 04/29/2025 (MT Newswires) -- Halmont Properties (HMT.V) overnight Monday reported decreased profit for the year ended Dec. 31, even as revenue increased.

The company reported net income for 2024 of $18.39 million, or diluted net income per common share of $0.1252, compared with $18.49 million, or diluted net income per common share of $0.1269, a year earlier. Revenue increased to $32.02 million compared with $27.97 million in 2023.

Halmont expanded its investments in forest properties by subscribing for an additional $21.7 million in participating preferred shares of Haliburton Forest, increasing its effective ownership to 59%. The company also completed the issuance of $50 million of series II convertible preferred shares.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
French carmakers target fourfold jump in EV sales by 2027
French carmakers target fourfold jump in EV sales by 2027
May 6, 2024
PARIS (Reuters) - France's car industry will aim to ramp up electric car sales fourfold by 2027 under a strategy agreement to be signed with the government on Monday, just as the president of China embarks on a state visit in the country. French President Emmanuel Macron has set a goal for the nation's carmakers to produce two million electric or...
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration
May 6, 2024
04:37 AM EDT, 05/06/2024 (MT Newswires) -- Lantern Pharma ( LTRN ) and Oregon Therapeutics are partnering to develop drug candidate XCE853 as a cancer treatment, the companies said Monday. Under the terms of the agreement, Lantern Pharma ( LTRN ) will receive equal intellectual property ownership and drug development rights in any newly discovered research findings or treatment strategies...
Japanese Yen Underperforms as Australian Dollar Leads G10 FX Higher
Japanese Yen Underperforms as Australian Dollar Leads G10 FX Higher
May 6, 2024
04:36 AM EDT, 05/06/2024 (MT Newswires) -- The Japanese yen fell against all major currencies in early European trade on Monday while the Australian dollar outperformed following a robust performance from risk assets in the Asian trading session. USD/JPY was the biggest mover among major currency pairs, rising 0.58% in Asia to be quoted around 153.72 following the European open....
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
May 6, 2024
04:56 AM EDT, 05/06/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Monday that data from a phase 2 trial of its drug candidate setanaxib in combination with pembrolizumab in patients with head and neck cancer met its secondary endpoints, including progress-free survival and overall survival. The randomized, placebo-controlled, double-blind study of 55 patients with squamous cell carcinoma of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved